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 Abstract
Background: Multidrug resistant tuberculosis(MDR-TB) is becoming a major threat to tuberculosis control programs in 
Ethiopia.
Objectives: To determine risk factors of  MDR-TB patients in Amhara National Regional State, Ethiopia.
Methods: Case-control study was conducted from May 2013 to January 2014. Resistance to rifampicin and isoniazid were 
done molecularly using line probe assay. TB patients infected with MDR-M.tuberculosis and non MDR-M.tuberculosis strain 
were considered as cases and controls, respectively. Data was collected using structured questionnaire with face to face in-
terview. Patients’ clinical record review was also done.Multivariate analysis was computed to determine the risk factors of  
MDR-TB. 
Results: A total of  153 MDR-TB and equal number of  non MDR-TB patients’ participated in the study. Patients 
who had TB treatment failure (AOR=13.5,CI=2.69-70), cavitations on chest x-ray (AOR=1.9,CI=1.1-3.38) and con-
tact with MDR-TB patients (AOR=1.4,CI=0.19-0.39) were more likely to be MDR-TB patients. Low monthly income 
(AOR=1.1,CI=0.34-0.47),alcohol consumption (AOR=1.5,CI=0.2-0.98) and young age (AOR=2.9,CI=1.07-7.68) were the 
other risk factors of  MDR-TB.  
Conclusions: TB treatment failure, cavitation on chest X-ray, contact with MDR-TB patients and low socioeconomic status 
were important risk factors for development of  MDR-TB. Therefore, strict adherence to directly observed therapy, appro-
priate management of  TB patients and advice on the value of  nutrients are helpful to control the spreading of  MDR-TB.
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Introduction
Drug resistance is a major threat to tuberculosis (TB) 
control programs worldwide1. Multidrug resistant TB 
(MDR-TB) is defined as a simultaneous resistance to at 
least rifampicin (RMP) and isoniazid (INH)2. Patients 
infected with MDR strains are less likely to be cured 
from TB particularly if  they are co-infected with HIV 
or suffer from other immuno suppressive diseases3. 
MDR-TB is associated with a two to four fold period of  
treatment, psychological problems, economic wastage, 
poor treatment adherence and consequently treatment 
failure4,5,6. It is also associated with higher case fatality 
rates (50 - 80%) as a result of  drug toxicity4,5.   
Globally, 3.5% of  new TB cases and 20.5% of  previ-
ously treated cases are estimated to have MDR-TB7. 
In developing countries, due to poverty, migration and 
HIV infection, MDR-TB is associated with spread and 
persistence in high incidence4,5,6. Despite the lack of  
comprehensive surveillance data from Africa, MDR-
TB has been recognized as an emerging public health 
concern. In South Africa, clusters of  MDR-TB cases 
have been documented in institutional and community 
settings among HIV-infected patients8.
Ethiopia is among the 27 countries with the highest 
TB burden in the world7. The annual TB incidence and 
prevalence of  Ethiopia is estimated to be 247 and 470 
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cases per 100,000 in 20139. These days, drug resistant 
TB has become a common problem and challenge in 
Ethiopia7. Drug resistant TB is estimated as 1.6% and 
12% among new and previously treated TB cases, re-
spectively7.
Factors such as inadequate chemotherapy, poor drug 
quality, poor adherence to treatment, treatment failure, 
prior treatment, cavity pulmonary TB, HIV infection 
and diabetes accounted for the development of  drug 
resistance in TB10,11. Of  these, the most powerful pre-
dictor for the presence of  MDR-TB is a previous his-
tory of  treatment of  TB10. Many new cases of  MDR-
TB develop due to error in TB management such as 
the use of  a single drug to treat TB, the addition of  a 
single drug to a failing regimen, the failure to identify 
pre-existing resistance, the initiation of  an inadequate 
regimen using first line anti-TB drugs10,11. Variations in 
bioavailability of  anti-TB drugs predispose the patient 
to the development of  MDR-TB10,11.            
Other major factors significantly contributing to the 
higher complexity of  the treatment of  MDR-TB is 
non- adherence to prescribed treatment12. Psychiatric 
illness, alcohol consumption, and travel to different 
places, symptom relief, adverse drug reactions, drug ad-
diction, homelessness and inability to afford treatment 
do predict non-adherence to treatment. Poor compli-
ance with treatment is also an important factor in the 
development of  acquired drug resistance10,12,13.    
Previous studies done in Ethiopia, reported that being 
male, prior exposure to anti-TB treatment, non-adher-
ence for first line anti-TB treatment, drug side effects 
during first line treatment, treatment not directly ob-
served with a health worker and interruption of  treat-
ment for at least a day were factors significantly associ-
ated with MDR-TB14,15.
It is known that epidemiologic information on risk 
factors of  MDR-TB is important for prevention and 
control of  the spread of  the disease in countries where 
drug resistance is a major threat. However, there is scar-
city of  information in the study area and at large to our 
country. Thus, the aim of  this study was to determine 
the potential risk factors for MDR-TB patients among 
presumptive MDR-TB patients in the Amhara National 
Regional State (ANRS), Ethiopia. 
Methods
Study design, period and setting
Unmatched case - control study was conducted from 
May 2013 to January 2014 in ANRS. The State of  Am-
hara is the second largest region of  Ethiopia that has 
an area of  157347sq.km16. It is located in the north 
western and north central part of  Ethiopia. Accord-
ing to the 2007 census, the region's population was 17, 
22197616. The region is divided into 11 administrative 
zones  with 151 Woredas. Out of  these, 128 are rural 
and 23 are town administration. ANRS  has over 500 
governmental and private health institutions that pro-
vide TB microscopy and directly observed treatment 
for short course (DOTS) centers14,16. Currently, Gondar 
University specialized and Borumeda Hospital are the 
only MDR-TB treatment initiation centers in the re-
gion. Data on risk factors was collected from MDR and 
non MDR-TB patients who had follow up in the above 
MDR-TB treatment initiation centers of  the region.
      
Sample size determination and sampling
The sample size for cases and controls was calculated 
using Epi Info 6.04 soft-ware by taking a proportion of  
males among the controls of  50% and among the cases 
of  69.5%10, 5% significance level, power (% chance of  
detecting) of  80%, a case to control ratio of  1: 1 and a 
non response rate of  10%. A total of  358 sample size 
was calculated. However, only 306 (153 cases and153 
controls) TB patients volunteered and participated in 
the study. All confirmed MDR-TB patients and patients 
with TB but sensitive to both RMP and INH were en-
rolled conveniently. 
Study population and participants
Study population included all presumptive MDR -TB 
patients living in ANRS during the study period. 
Cases were presumptive MDR-TB patients who were 
infected with MDR M. Tuberculosis confirmed with mo-
lecular line probe assay (LiPA) 
Controls were presumptive MDR-TB patients who 
were infected with M. tuberculosis sensitive to both RMP 
and INH as per the result of  LiPA.
Variables
MDR-TB was the dependent variable where as socio 
demographic factors, tuberculosis and its treatment re-
lated conditions were the independent variables. 
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Data collection
Specimens were collected from presumptive MDR-TB 
patients for Ziehl Neelsen stain and culture in Lowen-
stein Jensen medium. From smear and culture positive 
samples, DNA was extracted and resistance to rifampic-
in (RMP) and isoniazid (INH) were done molecularly 
using line probe assay (LiPA). Using a structured ques-
tionnaire data was collected by both face to face patient 
interviews and patient’s clinical record review. Health 
officers and nurses who were trained about MDR-TB 
and working at TB treatment initiation center collected 
the data. The main variables included in the study were 
age, sex, monthly income, HIV status, category of  TB 
treatment, number of  previous TB treatment,s treat-
ment history, alcohol consumption, smoking, history 
of  irregular treatment during intensive and continuous 
phase,  cavitations on chest x-ray, history of  close con-
tact with MDR-TB patients, housing condition and site 
of  tuberculosis .
Operational definitions of  terms according to 
WHO
New patients:  A case of  TB that has never had anti- 
TB treatment
Previously treated:  Patients that have received 1 
month or more of  anti-TB drugs in the past, may have 
positive or negative bacteriology and may have disease 
at any anatomical site.
Relapse: A patient declared cured or treatment com-
pleted of  any form of  TB in the past, but who reports 
back to the health service and is now found to be acid 
fast bacilli smear positive or culture positive.
Treatment failure: - A patient who is sputum smear or 
culture positive at 5 months or later during treatment. 
Defaulter:- A patient whose treatment was interrupted 
for 2 consecutive months or more.
Presumptive MDR-TB: Those TB patients who had 
any TB treatment failure, symptomatic close contact of  
confirmed MDR-TB cases, return after relapse, return 
after default and previously treated cases that remain 
smear positive at the end of  intensive phase.
Data management and statistical analysis 
Data was analyzed using Statistical Package for Social 
Sciences (SPSS) version 20 statistical software. Descrip-
tive statistics were computed to get summary values. 
Association between variables were determined using 
odds ratio and 95% CI. Multivariate analysis was run by 
selecting those variables that appeared to have a P-value 
of  < 0.05 in the bivariate analysis to control the con-
founding effect of  different variables while assessing 
the effect of  each variable on the likely hood of  MDR-
TB development. P-value of  < 0.05 was considered as 
statistical significance.
Ethical considerations
Ethical clearance was obtained from the Research and 
Ethical Review Board of  Bahir Dar University. Moreo-
ver, all patients gave written informed consent to par-
ticipate in this study. 
Results
Characteristics of  study participants
A total of  153 MDR-TB and equal number of  TB pa-
tients infected with non MDR strains participated in the 
study. Of  these, 88 (57.5%) and 90 (58.8%) were males 
in cases and controls, respectively. Eighty four (54.9%) 
of  the cases and 81 (52.9%) of  the controls were within 
the age ranges of  26 - 45 years. Detail characteristics of  
the study participants are presented in table 1.
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 Table.1. Sociodemographic characteristics of MDR-TB cases (N=153) and controls (N=153), ANRS, 2014. 





 COR (95% CI) 
Sex       
Male 88 (57.5) 90 (58.8) 1.1 (0.67 - 1.66) * 
Female 65 (42.5) 63 (41.2)         1 
Age category (Years)      
<  25 56 (36.6) 43 (28.1) 0.8 (0.48 -1.31) * 
26-45 84 (54.9) 81 (52.9) 0.3 (0.16 - 0.74) ** 
> 45 13 (8.5) 29 (19)     1 
Residence       
Urban 114 (74.5) 97 (63.4) 0.6 (0.36 - 0.97)  ** 
Rural 39 (25.5) 56 (36.6)     1 
Marital status       
Single 56 (37.2) 53 (34.6)       1 
Married 61 (39.9) 83 (54.3) 0.4 (0.18 - 0.7) ** 
Divorced/Widowed 35 (22.9) 17 (11.1) 0.5 (0.26 -1.02) * 
Educational status       
Illiterate 53 (34.6) 55 (36) 1.6 (0.65 - 3.68) * 
Up to elementary 52 (34) 61 (39.8) 0.8 (0.4 - 1.6) * 
High school 26 (17) 16 (10.5) 0.9 (0.45 - 1.87) * 
College & above 22 (14.4) 21 (13.7)   1 
Occupation       
Farmer 39 (25.5) 44 (28.8)      1 
Student 13  (8.5) 17 (11.1) 0.9 (0.38 - 2.07) * 
Merchant 13 (8.5) 17 (11.1) 0.9 (0.38 - 2.07) * 
House wife 37 (24.2) 29 (19) 1.5 (0.77 - 2.86) * 
Employee 22 (14.4) 22 (14.4) 1.2 (0.56 - 2.43) * 
Daily laborer 29 (19) 24 (15.7) 1.5 (0.75 - 2.9) ** 
Monthly income  (ETB)      
Up to 500 54 (35.3) 47 (30.7) 0.2 (0.04 - 0.85** 
501-1500 79 (51.6 80 (52.2) 0.4 (0.09 - 1.33* 
1501-2000 10 (6.5) 16 (10.5)  (0.29 - 1.12) * 
> 2001 10 (6.5) 3 (2.0)         1 
Key: ANRS (Amhara National Regional State), COR (Crude odds ratio), 1: Reference category, ** P-value < 0.05, * P - value > 0.05 
Tuberculosis related conditions
The majority of  participants had pulmonary TB in cas-
es 141 (92.2%) and controls 137 (89.5%). Proportion 
of  AIDS patients were more in cases 30 (19.6%) com-
pared to controls 21 (13.7%). Homeless participants 
accounted for 12 (7.8%) in MDR-TB patients and 6 
(3.9 %) in controls. Majority of  cases (62.1%) and 54 
(35.3%) of  controls had cavitation on chest x-ray. Of  
the 153 MDR-TB cases, 44 (28.8%) had history of  con-
tact with MDR- TB patients. In the control group, only 
22 (14.4%) had history of  close contact with MDR-TB 
patients. Living in a house of  mud floor was higher in 
the MDR-TB cases (83.7%) than in the control group 
(71.2%). The percentage of  alcohol drinkers was higher 
among cases (29.6%) than controls (13.1%)  (Table 2). 
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Of  the 153 MDR-TB cases, 1(0.7%) was a defaulter, 
135 (88.2%) were treatment failure, 14 (9.2%) were 
relapse and 3 (2%) were new cases. While in the con-
trols, defaulters were 3 (2%), treatment failures were 66 
(43.1%), relapses were 57 (37.3%) and new cases were 
26 (17%). Previous treatment for > 2 times with anti TB 
drug were encountered in 121(79.1%) and 89 (58.2%) 
of  the cases and controls, respectively. Irregular treat-
ment during intensive phase occurred in 22 (14.3%) 
of  cases and 9 (5.9%) of  controls. Moreover, irregu-
lar treatment during continuous phase occurred in 26 
(17%) of  the cases and 13 (7.9%) of  the controls. One 
hundred twenty nine MDR-TB cases (86.6%) and 100 
(67.1%) controls had history of  treatment at a health 
facility (Table 3).
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Table 2 Tuberculosis disease related conditions in each category (case/control), ANRS, 2014. 
     Characteristics 
       
Cases  




(N = 153) 
  
  
 COR (95% CI)         
  Number Percent Number Percent   
History of alcohol consumption            
Yes 33 21.6 20 13.1 0.6 (0.29- 0.94)***        
No 120 78.4 133 86.9  1 
Living situation            
Individually in a home 25 16.3 28 18.3 1 
Within family 116 75.8 119 77.8 0.92 (0.5 -1.67)* 
Homeless /prisoner 12 7.8 6 3.9 2.1 (0.75 - 5.65)** 
History of Contact with MDR- TB            
Yes 44 28.8 22 14.4 0.4 (0.23 - 0.14) ** 
No 109 71.2 131 85.6 1 
Floor of the  house           
Mud 128 83.7 109 71.2 2.1 (1.19 - 3.60)**       
Cement 25 16.3 44 28.8 1 
Have sewer in the  home           
Yes 30 19.6 69 45.1 1 
No 123 80.4 84 54.9            0.3 (0.18 - 0.49)***    
Number of people in a house           
Average (2) 32 20.9 32 20.9 1                              
Below average ( <2 ) 31 20.3 31 20.3                                           1.0 (0.49 - 2.03)* 
Above average ( > 2) 90 58.8 90 58.8  1.0 (0.56 -1.78) * 
HIV status           
HIV Negative 110 71.9 119 77.8 1 
HIV Positive 13 8.5 13 8.5 1.1(0.48 - 2.44)*                              
AIDS 30 19.6 21 13.7 1.5 (0.84 -2.86)* 
Site of  TB the patient has           
Pulmonary 141 92.2 137 89.5 1.4 (0.63 - 3.01) *   
Extra-pulmonary 12 7.8 16 10.6  1 
Had cavitations on chest X-ray           
Yes 95 62.1 54 35.3 3.0 (1.89 - 4.83)***       
No 58 37.9 99 64.7 1         
Key: ANRS (Amhara national Regional State), COR (Crude odds ratio),*** P-value < 0.001, ** P - value < 0.05, * P-value > 0.05 
Logistic regression analysis
After adjusting for possible confounding factors, MDR-
TB was significantly associated with previous  history 
of  TB  treatment failure (AOR=13.5, CI = 2.69 - 70), 
cavitation on chest x-ray (AOR= 1.9, CI = 1.1 – 3.38), 
young age (AOR = 2.9, 95% CI = 1.07 – 7.68),  low 
monthly income (AOR = 1.1, CI 0.34 - 0.47), history 
of   contact with MDR-TB patients (AOR = 1.4, CI = 
0.19-0.39) and alcohol consumption (AOR = 1.5, CI = 
0.2-0.98) (Table 4). 
TB patients who had previous history of  treatment fail-
ure were 13.5 times more likely to develop MDR-TB 
than those who completed the course of  TB treatment. 
Moreover, those TB patients who had >2 times previ-
ous anti - TB treatment were 1.9 times more likely to 
develop MDR-TB compared to those who had not. TB 
patients who had cavitations on chest x -ray were 1.9 
times more likely to have MDR-TB than those who had 
not. Patients whose ages were below 26 years old were 
2.9 times more likely to have MDR-TB than those TB 
patients with age group of  26 years and above (Table 4).
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Table 3 Tuberculosis treatment-related conditions in MDR-TB cases and controls ANRS, 2014. 
Variables Cases Percent Controls Percent COR (95% CI) 
Treatment history           
Previously untreated 6 3.9 22 14.4   1 
Previously treated 147 96.1 131 85.6  0.2 (0.1- 0.62)*** 
Category of TB-treatment           
Defaulters 1 0.7 3 2 2.9 (0.22 -37.4) *              
Treatment failure 135 88.2 66 43.1 17.7 (5.1- 60) ***              
Relapse 14 9.2 57 37.3 2.1 (0.56 - 8.05) *             
New case 3 2 26 17  1 
Number of previous treatment           
0 -1 32 20.9 64 41.8 1 
2 and above 121 79.1 89 58.2 2.6 (1.6 - 4.39)*** 
Place of TB treatment           
In home 20 13.4 49 32.9 0.3 (0.19-0.59)*** 
In health facility 129 86.6 100 67.1  1 
Private TB diagnostic & treatment 
center 
          
Yes 41 26.8 45 29.4 1.1 (0.7 - 1.9)*   
No 112 73.2 108 70.6  1 
       Irregular treatment during intensive 
phase 
     
Yes 22 14.4 9 5.9                          0.4 (0.17 - 0.84)**   
No 131 85.6 143 94.1            1 
Irregular treatment during continuous 
phase 
          
Yes 26 17 13 7.9                             0.5 (0.23-0.93)**   
No 127 83 139  92.1                         1
Previous treatment with insufficient 
duration 
          
Yes 10 6.5 11 7.2 1.0 (0.42 - 2.38)*   
No 143 93.5 142 92.8 1 
key: ANRS: Amhara National Regional State, COR (Crude Odds ratio),1(Reference category) 
        ***P-value < 0.001, ** P-value < 0.05, * P-value > 0.05 
                          372 373
Discussion
This study was conducted for the first time in the region 
to determine the risk factors for MDR-TB infection 
among presumptive MDR-TB patients. History of  TB 
treatment failure was one of  the strongest predictors for 
having MDR-TB. This conforms to other studies con-
ducted in different parts of  the world14, 17- 21. Similarly, 
a nationwide anti-TB drug resistance survey conducted 
Table 4. Multivariate analysis for the risk factors of multidrug-resistant tuberculosis ANRS, 2014. 
Characteristics Case Control     COR     AOR P-value 
Age of participants           
<  25 56 43 0.8 (0.48 -1.31) 2.9 (1.07 -7.68) 0.036 
26-45 84 81 0.3 (0.16 - 0.74)          2.2 (0.89 -5.49)        0.09 
>46 13 29   1   1   
Residence           
Urban 114 97 0.6 (0.36-0.97)                                                            0.5 (0.25 – 0.92)                 0.03 
Rural 39 56 1                                                     1   
Marital status           
Single 56 53 1  1    
Married 61 83 1.9 (0.98 - 3.9) 1.16 (0.52 - 2.58)    0.04 
Divorced/widowed 35 17 0.7 (0.42 - 1.15) 2.4 (0.89 - 6.57) 0.08 
Monthly income ( ETB)           
< 500 54    47 0.2 (0.04 - 0.85)  0.1 (0.34 - 1.47)                    0.003 
501-1500 79    80   0.4(0.09 -1.33  0.2 (0.03 - 0.79) 0.24 
1501-2000 10    16 (0.29 -1.12)      0.2 (0.03 - 0.75)            0.02 
> 2001 10    3       1             1   
Alcohol consumption           
Yes 33 20 0.6 (0.29 -1.00)  0.5 (0.2 - 0.98)          0.04 
No 120 133  1  1   
Contact with MDR-TB patients           
Yes 44 22 0.4 (0.24 - 0.74) 0.4 (0.19 - 0.39) 0.012 
No 109 131      1           1   
Floor of the  living house           
Mud 128 108 2.1 (1.19 - 3.6)    2.1 (0.93 – 4.4)           0.08 
Cement/Other 25 44  1 1   
Had cavitations on chest X-ray           
Yes 95 53 0.3 (0.21 -0.53)      1.9 (1.07 – 3.38)                  0.03 
No 58 98  1 1   
Category of TB treatment           
Defaulters 1 3 2.9 (0.22 - 37.3) 2.7 (0.49 -14.9) 0.26 
Treatment failure 135 66 17.7 (5.2 – 60.7) 13.5 (2.69 -70) 0.002 
Relapse 14 57 2.1(0.56-8.1) 5.2 (0.31 - 88) 0.25 
New case 3 26  1 1   
Number of previous treatment             
0 -1 32 62 1 1   
2 and above 120 88 0.2 (0.12 - 0.48) 1.9 (0.95 -3.61) 0.07 
Place of TB treatment           
Home 21 49 1 1    
Health facility 129 100 0.3 (0.19-0.59) 1.8 (0.9 -3.49) 0.09 
Irregular treatment during intensive phase           
Yes 22 9 0.4 (0.17 - 0.84)     1.1 (0.25 – 4.24)       0.97 
No 131 143  1        1   
Irregular treatment  during continuation phase           
Yes 26 17 0.5 (0.23 - 0.93)    0.8 (0.35 – 2.23)       0.89 
No 127 83 1  1   
Key: ANRS (Amhara National Regional State), COR (Crude odds ratio), AOR (Adjusted odds ratio) 
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Characteristics Case Control     COR     AOR P-value 
Age of participants           
<  25 56 43 0.8 (0.48 -1.31) 2.9 (1.07 -7.68) 0.036 
26-45 84 81 0.3 (0.16 - 0.74)          2.2 (0.89 -5.49)        0.09 
>46 13 29   1   1   
Residence           
Urban 114 97 0.6 (0.36-0.97)                                                            0.5 (0.25 – 0.92)                 0.03 
Rural 39 56 1                                                     1   
Marital status           
Single 56 53 1  1    
Married 61 83 1.9 (0.98 - 3.9) 1.16 (0.52 - 2.58)    0.04 
Divorced/widowed 35 17 0.7 (0.42 - 1.15) 2.4 (0.89 - 6.57) 0.08 
Monthly income ( ETB)           
< 500 54    47 .2 ( .04 - 0.85)  0.1 (0.34 - 1.47)                    0.003 
501-1500 79    80   0.4(0.09 -1.33  0.2 (0.03 - 0.79) 0.24 
1501-2000 10    16 (0. 9 -1.12)      0.2 (0.03 - 0.75)            0.02 
> 2001 10    3       1             1   
Alcohol consumption           
Yes 33 20 0.6 (0.29 -1.00)  0.5 (0.2 - 0.98)          0.04 
No 120 133  1  1   
Contact with MDR-TB patients           
Yes 44 22 0.4 (0.24 - 0.74) 0.4 (0.19 - 0.39) 0.012 
No 109 131      1           1   
Floor of the  living house           
Mud 128 108 2.1 (1.19 - 3.6)    2.1 (0.93 – 4.4)           0.08 
Cement/Other 25 44  1 1   
Had cavitations on chest X-ray           
Yes 95 53 0.3 (0.21 -0.53)      1.9 (1.07 – 3.38)                  0.03 
No 58 98  1 1   
Category of TB treatment           
Defaulters 1 3 2.9 (0.22 - 37.3) 2.7 (0.49 -14.9) 0.26 
Treatment failure 135 66 17.7 (5.2 – 60.7) 3.5 (2.69 -70) 0.002 
Relapse 14 57 2.1(0.56-8.1) 5.2 (0.31 - 88) 0.25 
New case 3 26  1 1   
Number of previous treatment             
0 -1 32 62 1 1   
2 and above 120 88 0.2 (0.12 - 0.48) 1.9 (0.95 -3.61) 0.07 
Place of TB treatment           
Home 21 49  1    
Health facility 129 100 0.3 (0.19-0.59) 1.8 (0.9 -3.49) 0.09 
Irregular treatment during intensive phase           
Yes 22 9 0.4 (0.17 - 0.84)     1.1 (0.25 – 4.24)       0.97 
No 131 143  1        1   
Irregular treatment  during continuation phase           
Yes 26 17 0.5 (0.23 - 0.93)    0.8 (0.35 – 2.23)       0.89 
No 127 83 1  1   
 
Key: ANRS (Amhara National Regional State), COR (Crude odds ratio), AOR (Adjusted odds ratio) 
in Ethiopia stated that 11.8% of  the MDR-TB cases 
had history of  anti-TB therapy while 1.6% were new-
ly diagnosed MDR-TB22. The association between TB 
treatment failure and MDR-TB might be related to  un-
satisfactory compliance by patients or clinicians, lack of  
supervision of  treatment, improper drug regimens and 
inadequate or irregular drug supply that may potentiate 
drug resistance14,17-21. Furthermore, those TB patients 
who had history of  > 2  times anti TB treatment were 
1.9 times more likely to be at risk of  developing MDR-
TB. This is in accordance with study done in Ethiopia14 
and Pakistan2. The association between increased num-
ber of  previous TB treatments and MDR-TB might be 
due to poor adherence of  patients that may potentiate 
secondary drug resistance.
Data on the relationship between cavitations on chest 
x-ray finding and MDR-TB is insufficient in the liter-
ature. In the present study lung cavities are a risk fac-
tor for MDR-TB. This finding was in agreement with 
studies conducted in Brazil23,24. The association be-
tween lung cavities and MDR-TB was attributable to 
existence of  a higher probability of  first step resistant 
mutants. The selection of  mutants is facilitated by the 
fast multiplication to up to 108 or 109 bacilli inside the 
cavities, due to the high level of  oxygenation and to the 
protection granted to the bacilli by thick walls which 
keep drugs from reaching adequate inhibitory concen-
trations. Concomitantly with inadequate treatments, 
cavities are a favorable environment for the develop-
ment of  MDR-TB 23,24.
An association between history of  close contact with 
MDR-TB patients and subsequent MDR-TB cases in 
this study conforms to other studies18,19,25.  The associ-
ation between history of  close contact with MDR-TB 
patients and MDR-TB strain would be attributable to 
acquiring of  primary drug resistant bacteria from the 
patient. 
Many studies reported that poor treatment adherence 
and irregular treatment were the strongest risk factors 
for development of  MDR-TB14,23,26. This study also 
revealed that the rate of  MDR-TB was higher among 
patients who did not adhere to the proper treatment 
during intensive and continuous phase. This might be 
associated with increased bacterial death and growth cy-
cles, giving more opportunities for individual mutations 
of  different independent genes to accumulate27. 
In this study, young age presumptive MDR-TB pa-
tients were more prone to MDR-TB which calls for 
some concrete steps to be taken to combat this disease 
in order to save the economically productive popula-
tion. This finding is in accordance with other reports 
in Ethiopia2,14. To the contrary, a study in other setting 
stated that MDR-TB was more prevalent among old-
er age groups20. Moreover, regarding socio-economic 
factors, majority of  MDR-TB patients were from low 
socioeconomic status2,28,29. This might be due to poor 
compliance with TB treatment often due to poor liv-
ing and housing condition and limited access to medical 
treatment and health care services which might facili-
tate the spread of  infectious bacilli. Hence, these lower 
socioeconomic groups should be the highest priority in 
MDR-TB prevention and control efforts.
In the present study, alcohol consumption was also one 
of  the risk factor for the development of  MDR-TB. It 
might be associated with its significant role for default 
and failure rate among new TB cases. Hence, it increas-
es the rate of  MDR-TB cases. In another studies also 
alcohol consumption was frequently reported as one of  
the risk factors for MDR TB23 and was also a risk factor 
for default24.
Similar to previous studies, HIV status had no signif-
icant association with MDR-TB14,23,30. In addition, in 
France31 and Ukraine32 being HIV positive was associ-
ated with primary MDR-TB but it was not associated 
with secondary MDR-TB in France31. This is because 
HIV is one risk factor for drug susceptible TB, which 
is associated to immune system suppression. Moreover, 
a study in South Africa33 showed that in retreated pa-
tients, HIV had no significant association with MDR-
TB. Although, we did not differentiate being HIV pos-
itive or treatment for TB which came first, greater than 
95% of  the MDR-TB study participants in our study 
were patients who had a history of  TB treatment and 
the result could have been different if  all study partici-
pants were primary MDR-TB cases rather than second-
ary MDR-TB cases.
The major strength of  this survey was inclusion of  
presumptive MDR-TB patients living in all parts of  
the Amhara Region and selecting the cases and con-
trols based on the result of  molecular technique, line 
probe assay. However, this study could not differentiate 
whether MDR-TB cases were primarily MDR-TB or 
secondary MDR-TB. 
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Conclusion and recommendations
This study revealed important information on risk fac-
tors for MDR-TB patients that would provide base line 
information for high TB burden countries like Ethio-
pia. In this survey, previous TB treatment failure, hav-
ing cavitations on chest x-ray, contact with MDR-TB 
patients and low socioeconomic status were the major 
predictors for having MDR–TB. Therefore, strict ad-
herence to DOTS, basic TB infection control practic-
es, appropriate management of  TB patients and advice 
on the value of  nutrients are imperative to control the 
spreading of  MDR-TB.
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